SILVER SPRING
Saphnelo Pen cleared for SLE self-administration
- Sponsor
- AstraZeneca $AZN
- Drug
- Saphnelo · anifrolumab
- Indication
- systemic lupus erythematosus
FDA approved AstraZeneca's Saphnelo Pen autoinjector for once-weekly subcutaneous self-administration in adult SLE patients.
What this means
Saphnelo is an antibody treatment for lupus that works by blocking certain immune system proteins called interferons, which can drive inflammation. Today FDA cleared a new pen device that lets patients give themselves weekly Saphnelo injections at home instead of needing clinic visits. This change could make treatment more convenient for people with lupus, potentially helping them stick to their medication schedule better.